{"id":"https://openalex.org/W2016402642","doi":"https://doi.org/10.1097/00005344-198505000-00019","title":"Application of Pharmacokinetic-Pharmacodynamic Modelling for the Comparison of Quinazoline \u03b1-Adrenoceptor Agonists in Normotensive Volunteers","display_name":"Application of Pharmacokinetic-Pharmacodynamic Modelling for the Comparison of Quinazoline \u03b1-Adrenoceptor Agonists in Normotensive Volunteers","publication_year":1985,"publication_date":"1985-05-01","ids":{"openalex":"https://openalex.org/W2016402642","doi":"https://doi.org/10.1097/00005344-198505000-00019","mag":"2016402642","pmid":"https://pubmed.ncbi.nlm.nih.gov/2410686"},"language":"en","primary_location":{"id":"doi:10.1097/00005344-198505000-00019","doi":"https://doi.org/10.1097/00005344-198505000-00019","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00005344-198505000-00019","pdf_url":null,"source":{"id":"https://openalex.org/S61167191","display_name":"Journal of Cardiovascular Pharmacology","issn_l":"0160-2446","issn":["0160-2446","1533-4023"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cardiovascular Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113446026","display_name":"Peter Meredith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802797558","display_name":"Stobhill Hospital","ror":"https://ror.org/04pc31859","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800201399","https://openalex.org/I2802797558"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter A. Meredith","raw_affiliation_strings":["University of Glasgow, Department of Materia Medica, Stobhill General Hospital, Glasgow, Scotland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Glasgow, Department of Materia Medica, Stobhill General Hospital, Glasgow, Scotland","institution_ids":["https://openalex.org/I2802797558","https://openalex.org/I7882870"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110855679","display_name":"Henry L. Elliott","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802797558","display_name":"Stobhill Hospital","ror":"https://ror.org/04pc31859","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800201399","https://openalex.org/I2802797558"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Henry L. Elliott","raw_affiliation_strings":["University of Glasgow, Department of Materia Medica, Stobhill General Hospital, Glasgow, Scotland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Glasgow, Department of Materia Medica, Stobhill General Hospital, Glasgow, Scotland","institution_ids":["https://openalex.org/I2802797558","https://openalex.org/I7882870"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111948058","display_name":"Andrew W. Kelman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802797558","display_name":"Stobhill Hospital","ror":"https://ror.org/04pc31859","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800201399","https://openalex.org/I2802797558"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andrew W. Kelman","raw_affiliation_strings":["University of Glasgow, Department of Materia Medica, Stobhill General Hospital, Glasgow, Scotland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Glasgow, Department of Materia Medica, Stobhill General Hospital, Glasgow, Scotland","institution_ids":["https://openalex.org/I2802797558","https://openalex.org/I7882870"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103336920","display_name":"John L. Reid","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802797558","display_name":"Stobhill Hospital","ror":"https://ror.org/04pc31859","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800201399","https://openalex.org/I2802797558"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John L. Reid","raw_affiliation_strings":["University of Glasgow, Department of Materia Medica, Stobhill General Hospital, Glasgow, Scotland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Glasgow, Department of Materia Medica, Stobhill General Hospital, Glasgow, Scotland","institution_ids":["https://openalex.org/I2802797558","https://openalex.org/I7882870"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.5839,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.92477597,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"7","issue":"3","first_page":"532","last_page":"537"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.5654000043869019,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.5654000043869019,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.18490000069141388,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.08649999648332596,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prazosin","display_name":"prazosin","score":0.9150000214576721},{"id":"https://openalex.org/keywords/doxazosin","display_name":"doxazosin","score":1.0},{"id":"https://openalex.org/keywords/trimazosin","display_name":"trimazosin","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetic-pharmacodynamic-modeling","display_name":"pharmacokinetic-pharmacodynamic modeling","score":0.8820000290870667},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.8539999723434448},{"id":"https://openalex.org/keywords/renal-clearance","display_name":"renal clearance","score":0.734000027179718},{"id":"https://openalex.org/keywords/antihypertensive-effect","display_name":"antihypertensive effect","score":0.8650000095367432},{"id":"https://openalex.org/keywords/effect-compartment","display_name":"effect compartment","score":0.800000011920929},{"id":"https://openalex.org/keywords/alpha-blockers","display_name":"alpha-blockers","score":0.8100000023841858},{"id":"https://openalex.org/keywords/normotensive-volunteers","display_name":"normotensive volunteers","score":0.7179999947547913}],"concepts":[{"id":"https://openalex.org/C2777590997","wikidata":"https://www.wikidata.org/wiki/Q419939","display_name":"Doxazosin","level":3,"score":0.9588128328323364},{"id":"https://openalex.org/C2780648677","wikidata":"https://www.wikidata.org/wiki/Q425296","display_name":"Prazosin","level":4,"score":0.9173754453659058},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7274892330169678},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7225631475448608},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5635159015655518},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5062023997306824},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.4395880699157715},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.41344061493873596},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.4104786515235901},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24954760074615479},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.10534930229187012},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.053369879722595215}],"mesh":[{"descriptor_ui":"D000316","descriptor_name":"Adrenergic alpha-Agonists","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007700","descriptor_name":"Kinetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008433","descriptor_name":"Mathematics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011187","descriptor_name":"Posture","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011224","descriptor_name":"Prazosin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D011224","descriptor_name":"Prazosin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D017292","descriptor_name":"Doxazosin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00005344-198505000-00019","doi":"https://doi.org/10.1097/00005344-198505000-00019","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00005344-198505000-00019","pdf_url":null,"source":{"id":"https://openalex.org/S61167191","display_name":"Journal of Cardiovascular Pharmacology","issn_l":"0160-2446","issn":["0160-2446","1533-4023"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cardiovascular Pharmacology","raw_type":"journal-article"},{"id":"pmid:2410686","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2410686","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of cardiovascular pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2114891723","https://openalex.org/W1973413920","https://openalex.org/W2074705065","https://openalex.org/W2015482393","https://openalex.org/W2093255760","https://openalex.org/W2058883847","https://openalex.org/W2081122970","https://openalex.org/W2417009751","https://openalex.org/W2023070624","https://openalex.org/W2127421332"],"abstract_inverted_index":{"Prazosin,":[0],"doxazosin,":[1],"and":[2,20,50,97,108,136,153],"trimazosin":[3,53,98,130],"are":[4],"structural":[5],"analogues":[6],"with":[7,117,149],"relatively":[8],"selective":[9],"peripheral":[10],"alpha":[11],"1-adrenoceptor":[12],"antagonist":[13],"properties.":[14],"The":[15,36,77,103,126],"relationships":[16],"between":[17],"the":[18,62,122],"pharmacokinetics":[19],"pharmacodynamics":[21],"for":[22,43,52,67,121],"these":[23],"three":[24],"drugs":[25],"have":[26],"been":[27],"studied":[28],"following":[29],"acute":[30],"intravenous":[31],"administration":[32],"in":[33],"normotensive":[34],"subjects.":[35],"mean":[37,63],"terminal":[38,64],"elimination":[39,65],"half-life":[40,66],"(+/-":[41],"SD)":[42],"prazosin":[44,80,107],"was":[45,54,69,86,131,137],"2.0":[46],"+/-":[47,58,74,83,94,100],"0.4":[48],"h,":[49,60],"that":[51,89],"comparable":[55],"at":[56,72],"3.1":[57],"0.3":[59],"whilst":[61],"doxazosin":[68,92,109],"significantly":[70],"longer":[71],"9.4":[73],"1.5":[75],"h.":[76],"clearance":[78],"of":[79,90,106,129],"(mean,":[81],"327":[82],"78":[84],"ml/min)":[85,96],"greater":[87],"than":[88],"both":[91,150],"(139":[93],"30":[95],"(67":[99],"29":[101],"ml/min).":[102],"hypotensive":[104],"effects":[105],"were":[110],"fitted":[111,140],"to":[112,133,141],"an":[113,145],"integrated":[114],"pharmacokinetic-pharmacodynamic":[115],"model":[116,143],"similar":[118,134],"resulting":[119],"values":[120],"parameter":[123],"describing":[124],"responsiveness.":[125],"pharmacodynamic":[127],"profile":[128],"subjected":[132],"analysis":[135],"most":[138],"appropriately":[139],"a":[142],"incorporating":[144],"effect":[146],"compartment":[147],"associated":[148],"parent":[151],"drug":[152],"its":[154],"major":[155],"metabolite":[156],"1-hydroxy":[157],"trimazosin.":[158]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}